Astellas Pharma completes phase III in Japan for UMN-0502, a seasonal influenza vaccine

The recombinant seasonal influenza HA vaccine ASP7374 contains three different strains of antigens and has been produced by a cell-culture manufacturing method employing the Baculovirus Expression Vector System (BEVS). The vaccine was developed in collaboration with UMN Pharma.

Astellas Pharma news release, May 30, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny